Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

Amgen’s immuno-oncology drug scores in skin cancer

Firm hoping its novel treatment will be on the market be the end of this year

- PMLiVE

Amgen decision on brodalumab unsettles anti-IL-17 class

Move made following data found linking the drug to suicidal thoughts

Amgen appoints Jonathan Graham general counsel and secretary

He will succeed David Scott who is retiring

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

FDA panel backs Amgen’s T-Vec for melanoma

Approved by a panel of 22 to one despite questions on its impact on survival

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

- PMLiVE

FDA clears Amgen’s Corlaner for heart failure

It is the firm’s first cardiovascular product to gain approval

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

- PMLiVE

Dr. Reddy’s enters €118m product agreement with UCB in India

Portfolio acquisition will expand firm’s therapy footprint

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

- PMLiVE

Amgen gets quick US review for Kyprolis

To be considered as a second-line therapy for multiple myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links